Anand Rathi has reiterated its BUY rating on Carysil, raising the 12-month price target to Rs1,265. The report highlights strong Q2 results with revenue, EBITDA, and PAT growing 16%, 24%, and 62% year-on-year, respectively. Despite margin contraction due to product mix and costs, the brokerage expects sustained growth with revenue and PAT clocking 17% and 25% CAGR over FY25-28.